Continuous crystallization of carbamazepine | Chemical & Engineering News
Volume 95 Issue 26 | p. 9 | Concentrates
Issue Date: June 26, 2017

Continuous crystallization of carbamazepine

Chemists build proof-of-concept system to evaluate control strategies and risks
Department: Science & Technology
Keywords: process chemistry, continuous manufacturing, continuous crystallization, carbamazepine

As continuous manufacturing makes inroads in drug production, the process of continuous crystallization—in which active pharmaceutical ingredients are purified via solidification from a liquid phase—has proven to be a major roadblock. Looking to understand the risks involved with such systems and how they might be mitigated, scientists led by Celia N. Cruz at the U.S. Food & Drug Administration’s Office of Pharmaceutical Quality designed and built a lab-scale continuous crystallization platform for the anticonvulsant compound carbamazepine (Org. Process Res. Dev. 2017, DOI: 10.1021/acs.oprd.7b00130). Carbamazepine has four crystalline polymorphs, making it a good model compound for troubleshooting. The continuous crystallization system uses an automated, two-stage mixed-suspension and mixed-product removal platform and integrates two process analytical technology tools, Raman microscopy and focused-beam reflectance microscopy, to monitor the crystallization process in real time. The researchers were able to use the analytical tools to address two major problems with continuous crystallization—clogging and particle settling. They plan to optimize the system further to evaluate more advanced strategies for controlling continuous crystallization processes.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment